BIORCHESTRA
Business Services · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Techno 4-ro Unit B 17, Yuseong-gu, Daeje...Phone Number
+82 428631013Website
www.biorchestra.comRevenue
$24.3 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
1
1
1
1
1
About BIORCHESTRA
BIORCHESTRA, with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA, is an innovative biotech developing ribonucleic acid (RNA) based therapeutics. The company's goal is to change the therapeutic paradigm from symptoms treatment to diseases modifying therapeutics in neurodegenerative and other diseases. The BMD is a therapeutic agent development platform that can control microRNAs that regulate multiple messenger RNAs (mRNAs) involved in pathological factors related to diseases. The company believes that exclusively targeting single pathological protein, such as A or tau, like most candidate AD therapies of other pharmaceutical companies is too late in the disease course to halt the progression of AD. This upstream regulation with anti-sense oligonucleotide aims to reverse the epigenetic changes in the AD brain induced by the overexpression of target microRNA-485-3p, which the company has proven to induce A/tau production, cognitive impairment and a reduction in synaptRead more
BIORCHESTRA Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BIORCHESTRA your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if BIORCHESTRA is spiking on competitors!
Check if BIORCHESTRA has recently received funding, and reach out quickly before it becomes old news!
Congratulate Masked Content for being promoted to Masked Content at BIORCHESTRA
Product Launch: Get notified when BIORCHESTRA launches new products
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if BIORCHESTRA had a recent Job posting/layoffs
Earning: See what the market has to say on BIORCHESTRA recently announced quarterly report
Funding: Get notified immidiatlly once BIORCHESTRA has new funding data
BIORCHESTRA, which may be a good buyer, showed buying intent in Masked Content Topic
Recommended Actions
Reach out to Masked Content who joined BIORCHESTRA as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
BIORCHESTRA is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BIORCHESTRA is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BIORCHESTRA.
BIORCHESTRA financials insights
Gather financial insights about BIORCHESTRA, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2022
Series C
$45M
BIORCHESTRA Tech Stack
A closer look at the technologies used by BIORCHESTRA
See more technologies
Most Recent Scoops
New Hire
Executive Move
New Hire
Executive Move
Funding
New Hire
Executive Move
BIORCHESTRA News & Media
BIORCHESTRA Wins Grand Prize in 2023 Merck Advance Biotech Grant Program
Recognition of outstanding in-vivo outcomes from a lead RNA program in CNS Underpinned by proprietary IV-formulated, Brain-targeting Ribonucleic Acid Interference (RNAi) Nanomedicine (BTRiNTM) platform BIORCHESTRA to receive in-kind products and services from Merck Group CAMBRIDGE, Mass. and DAEJEON, South Korea, July 17, 2023 /PRNewswire/ -- BIORCHESTRA, a biotherapeutics company focused on the treatment of rare and degenerative diseases within the Central Nervous System (CNS), today announcedBIORCHESTRA Invited to Present Update on Central Nervous System Lead Program (BMD-001) and IV-Formulated siRNA Data at BIO2023 International Conference
Presentation:"Successfully Achieving Intravenous (IV)-formulated RNA Delivery to the Brain, Evidence of Efficacy" scheduled for June 08, 2023, 12:00 p.m. ET, Room 104A Pioneering IV-formulated inert drug delivery platform targeting neurodegenerative diseases Lead program (BMD-001) advancing to IND IV-formulated ASO and siRNA encapsulation strategies with compelling in-vivo outcomes Drug delivery platform expanded to previously inaccessible neurological diseases, including brain cancers CAMBRIDGEBIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins ... - Yahoo Finance
BIORCHESTRA, a biotherapeutics company focused on rare and degenerative diseases within the Central Nervous System (CNS), announced today that the company's Scientific Founder, Chairman, and Chief Executive Officer, Dr. Branden Ryu, has been invited by the Korean Government to join the Official State visit to the U.S.BIORCHESTRA Scientific Founder, Chairman, and Chief Executive Officer Joins the Republic of Korea (ROK) Official State Visit to the United States
The Official State visit by the President of the Republic of Korea marks the 70th anniversary of the U.S.-ROK alliance, which is advancing peace, stability, and prosperity for the two countries, for the Asia-Pacific region, and globally President Yoon Suk Yeol and First Lady Kim Keon Hee of the Republic of Korea are leading the Official State visit BIORCHESTRA Founder, Chairman, and Chief Executive, Dr. Branden Ryu, has been invited to join the Official delegation and will
Read more news
Top Business Services Companies
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BIORCHESTRA
Sign Up For FreeTo access detailed company insights
BIORCHESTRA, with offices in Daejeon, South Korea, and Cambridge, Massachusetts, USA, is an innovative biotech developing ribonucleic acid (RNA) based therapeutics. The company's goal is to change the therapeutic paradigm from symptoms treatment to diseases modifying therapeutics in neurodegenerative and other diseases. The BMD is a therapeutic age... Read More
